Medications for Progressive Supranuclear Palsy: A Note of Caution

Ooi, Evelyn MD

Assistant Professor of Clinical Neurology and Assistant Attending Neurologist, NewYork-Presbyterian/Weill Cornell Medical Center

Neurology Alert 43(7):p 52-53, March 2024.

SYNOPSIS: In this post hoc secondary analysis of a Phase II/III randomized clinical trial of davunetide for progressive supranuclear palsy (PSP), investigators found that patients with PSP prescribed benzodiazepine derivatives experienced more rapid worsening of their PSP Rating Scale scores over time.

SOURCE: Iyer JM, Gunzler D, Lang AE, et al. Concomitant medications for progressive supranuclear palsy: A secondary analysis of a randomized clinical trial. JAMA Neurol 2024; Jan 22. doi:10.1001/jamaneurol.2023.5215. [Online ahead of print].